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Objective: The objective of this in vivo study was to compare the incidence of vasodilation 
in guinea pigs following topical administration of bimatoprost ophthalmic solutions 0.01% 
and 0.03%.
Methods: The study comprised 20 guinea pigs assigned to 2 treatment groups (10 per   treatment 
group) to receive either bimatoprost 0.01% or bimatoprost 0.03%. Animals were hand-held 
under 2.75 × magnification to score ocular vasodilation (a measure of hyperemia), using a 
scoring system developed at Alcon Research, Ltd. Following baseline ocular scoring, each 
animal received a 30 µL dose to the left eye of either bimatoprost 0.01% (3 µg) or bimatoprost 
0.03% (9 µg). Vasodilation was again scored at 1, 2, 3, 4, 5 and 6 hours after dosing. Incidence 
of vasodilation was calculated as the percent of total eyes in each 2-hour time interval with 
scores $2.
Results: The incidence of vasodilation was higher in the bimatoprost 0.01% treatment group 
(range, 45.0% to 60.0%) than the bimatoprost 0.03% treatment group (range, 30.0% to 52.2%) 
at all post-dosing time points.
Conclusion: The 2 bimatoprost formulations elicited ocular vasodilation of long duration 
(.6 hours) in the guinea pig model, with the bimatoprost 0.01% treatment group showing a 
higher incidence of ocular vasodilation than the bimatoprost 0.03% treatment group. Further 
clinical studies would be needed to determine whether the higher incidence of vasodilation may 
also be attributed to the increased BAK concentration in the bimatoprost 0.01% formulation.
Keywords: bitamoprost, ocular vasodilation, hyperemia
Introduction
The goal of therapy for patients with glaucoma is prevention of progressive optic 
nerve damage, which is achieved by lowering the intraocular pressure (IOP).1 The 
prostaglandin analogs (PGA) latanoprost ophthalmic solution 0.005% (Xalatan®, Pfizer, 
New York, NY, USA), travoprost ophthalmic solution 0.004% (TRAVATAN®, Alcon 
Laboratories, Inc., Fort Worth, TX, USA), and bimatoprost ophthalmic solution 0.03% 
(Lumigan®, Allergan, Inc., Irvine, CA, USA), have become the most prominent topical 
treatments for ocular hypertension and open-angle glaucoma due to their potency and 
efficacy at lowering IOP and their favorable safety profile.1,2
Bimatoprost is an ethyl amide pro-drug derivative of the potent but non-selective FP 
prostaglandin receptor agonist; 17-phenyl-trinor PGF2α.3,4 Studies conducted on labo-
ratory animals have demonstrated the topical and systemic safety profiles of bimato-
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prost.5 However, several clinical trials demonstrated that the 
most common ocular side effect of bimatoprost in humans 
is ocular hyperemia.2,6 Bimatoprost 0.03% is preserved with 
0.005% benzalkonium chloride (BAK). Bimatoprost 0.01% 
is a new formulation approved in some countries, containing 
the same active ingredient, but in lower concentration, and a 
4-fold increase in the amount of BAK (0.02%).
Conjunctival hyperemia is a non-specific clinical term that 
implies vasodilation and the resultant increased blood supply 
to the conjunctival blood vessels.7 Ocular h  yperemia is caused 
by pharmacologic and/or i  nflammatory   mechanisms and is 
a very common side effect of IOP-lowering medications,8 
with p  rostaglandin analogs being   associated with the high-
est   incidences of hyperemia.9 The rate of hyperemia of 
bimatoprost, as listed in the product labeling, ranges from 
15% to 45%.10
The objective of this study was to compare the incidence 
of vasodilation in guinea pigs following topical ocular 
administration of bimatoprost 0.01% and bimatoprost 
0.03%.
Materials and methods
Animals
Twenty Hartley Outbred guinea pigs weighing 771 to 1078 g 
were obtained from Charles River Laboratories (Montreal, 
Quebec, Canada). Animals were divided into 2 groups, 10 
animals per group, to receive either commercially   available 
bimatoprost 0.01% (Lumigan 0.01%, Allergan Inc., Ontario, 
Canada) or bimatoprost 0.03% (Lumigan 0.03%, Allergan 
Inc., Irvine, CA, USA). Animals were housed individually 
and had unrestricted access to guinea pig chow and water.
Animals were handled and maintained according to the 
principles of the Declaration of Helsinki and in accordance 
with the Guiding Principles in the Care and Use of Animals. 
The study was approved by Alcon Research Ltd., Animal 
Study Review Board and followed the Association for 
Research in Vision and Ophthalmology (ARVO) guidelines 
for the use of animals.
Study design
Animals were hand-held under 2.75× magnification to score 
the magnitude of ocular vasodilation using a scoring system 
developed at Alcon Research, Ltd.11,12 Animals were selected 
for the study if the vasodilation score at baseline measure-
ment was 0 (zero). After baseline scoring, all animals in 
each group received three 10 µL aliquots (approximately 
3 minutes apart), of either bimatoprost 0.01% (3 μg) or 
bimatoprost 0.03% (9 μg) in the left eye only. Vasodilation 
was scored again using the same scoring system at 1, 2, 3, 
4, 5, and 6 hours after dosing.
Alcon-developed hyperemia  
scoring system
Area of vasodilation
0 =   Normal appearance of vessels at limbus and on rectus 
muscle
1 =   Enlargement of vessels normally visible at limbus and 
on rectus muscle
2 = Branching of vessels at limbus, new vessels are visible
3 = New vessels visible in open bulbar conjunctival areas
4 = Diffuse redness in open bulbar conjunctival areas
        0 and 1 are normal scores; 2, 3 and 4 represent adverse 
events.
Data calculation
Data were reported as percent incidence of vasodilation 
at 2-, 4-, and 6-hour intervals following dosing. Percent 
incidence is the total number of scores $2 divided by the 
number of observations per group. In this study with 10 
treated eyes per group and time points at 1, 2, 3, 4, 5, 6 hours 
after dosing, the 2-hour interval had 20 observations per 
treatment group (cumulative observations of hours 1 and 2). 
The 4-hour and 6-hour intervals, had 40 and 60 observa-
tions, respectively (cumulative observation of hours 1 to 4 
and hours 1 to 6, respectively). For example, if at the 4-hour 
interval there were 8 observations of vasodilation scores 
$2, then the percent incidence of vasodilation would be 
20% (8/40 × 100).
Results
The incidence of vasodilation was higher in the bimatoprost 
0.01% treatment group (range, 45.0% to 60.0%) than in the 
bimatoprost 0.03% treatment group (range, 30.0% to 52.2%) 
at all time points following dosing (Table 1).
Discussion
Glaucoma is an optic neuropathy characterized by increa-
sed IOP and progressive optic nerve damage. If left 
untreated, glaucoma can cause irreversible vision loss 
and is   considered the second leading cause of blindness 
in the world.13,14 Management of glaucoma aims to reduce 
IOP using topical pharmacotherapy, such as prostaglandin 
  analogs. Today, prostaglandin analogs are used as   first-line 
therapy for glaucoma due to their efficacy at reducing IOP 
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and their mild side effect profile, replacing the β-blockers 
for these indications.15
Because glaucoma is a chronic condition, once 
topical therapy is initiated, many patients continue to 
use their IOP-lowering therapy for the rest of their lives, 
  producing   long-term exposure to the various excipients and 
  preservatives used in these medications, which have been 
shown to cause corneal and conjunctival toxicity.8,16,17 Previ-
ous studies have shown that as many as 40% of glaucoma 
patients use more than one topical medication,18 and BAK 
is the most common preservative used in these preparations. 
Therapeutic regimens consisting of multiple BAK-containing 
medications can induce and/or exacerbate ocular toxicity, 
such as corneal epithelial cell dysfunction, altering the shape 
of the cornea and the consequential effect on accurate IOP 
measurement,16 and inflammatory and toxic effects on the 
conjunctiva.8,17 BAK has been shown to be responsible for 
at least part of the hyperemia associated with IOP-lowering 
therapy, as evidenced by a reduction of conjunctival hyper-
emia in patients who changed to a BAK-free prostaglandin 
analog after being treated with a BAK-preserved prostaglan-
din analog.19 Therefore, a BAK-free prostaglandin analog 
would decrease the load of this preservative on the ocular 
surface for patients using multiple topical medications.20
The incidence of hyperemia caused by IOP-lowering 
medications is highly variable, depending on the meth-
ods and analyses of the various clinical trials. The rate 
of hyperemia of bimatoprost ranges from 15% to 45%.10 
This side effect is theorized to be due to the vasodilation 
of the conjunctival vessels due to exposure to nitric oxide 
(NO), resulting from prostaglandin analog-induced over-
production of NO synthase,21 but not due to conjunctival 
inflammation.7,8,22 Additionally, Guenoun et al reported 
that although latanoprost contains higher concentration of 
BAK than the bimatoprost 0.03% formulation, it caused 
less hyperemia than bimatoprost 0.03%, suggesting that 
hyperemia is not solely a direct consequence of BAK toxic-
ity, but also can be attributed to the prostaglandin analog 
molecule.8
In this study, guinea pigs exposed to bimatoprost 
0.01% and bimatoprost 0.03% developed ocular vaso-
dilation within 2 hours after dosing, which lasted for 
more than 6 hours. Exposure to bimatoprost 0.01% 
caused higher incidences of vasodilation than exposure 
to bimatoprost 0.03% at all calculated intervals after dos-
ing. The use of the incidence at individual time points 
helps in demonstrating the onset and duration of vasodila-
tion. This study demonstrated that the 2 formulations of 
bimatoprost induced vasodilation soon after instillation, 
as evidenced by 2-hour percent incidence of 45% and 30% 
for bimatoprost 0.01% and bimatoprost 0.03%, respec-
tively, and that the vasodilation lasted for at least 6 hours 
after dosing, based on the 4- and 6-hour incidence data. It 
is important to know that despite the lower concentration 
of bimatoprost 0.01%, the incidence of vasodilation was 
higher in this treatment group than the bimatoprost 0.03% 
treatment group. This higher incidence of vasodilation in 
the bimatoprost 0.01% formulation may be attributed to 
the 4-fold increase in the amount of BAK in this formu-
lation (0.02%), as compared to the bimatoprost 0.03% 
  formulation (0.005%).
This in vivo animal study assessed vasodilation, a 
relative indicator of hyperemia, after a single exposure to 
bimatoprost. Therefore, the outcome of the application of 
this model to multiple doses of bimatoprost is unknown. For 
this reason, results of this in vivo study should be confirmed 
in clinical studies.
Conclusion
This study demonstrates that both bimatoprost 0.01% and 
bimatoprost 0.03% formulations elicit ocular vasodilation at 
early post-instillation time points that lasts for longer than 6 
hours in the guinea pig model, with the bimatoprost 0.01% 
treatment group showing a higher incidence of vasodila-
tion than the bimatoprost 0.03% treatment group. Further 
clinical studies would be needed to determine whether the 
higher incidence of vasodilation may also be attributed to 
the increased BAK concentration in the bimatoprost 0.01% 
formulation.
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